| Gene Symbol |
TGFBR1 |
| Full Name |
Transforming Growth Factor Beta Receptor 1 |
| Chromosomal Location |
9q22 |
| NCBI Gene ID |
7046 |
| OMIM |
190181 |
| Ensembl ID |
ENSG00000106799 |
| UniProt ID |
P36897 |
| Associated Diseases |
Marfan Syndrome, Loeys-Dietz Syndrome, Alzheimer's Disease, Parkinson's Disease |
Transforming Growth Factor Beta Receptor 1 (TGFBR1) is a cell surface receptor that mediates signaling of TGF-β cytokines, playing crucial roles in cell growth, differentiation, apoptosis, and immune regulation.[1] In the nervous system, TGFBR1 signaling is essential for neurodevelopment, synaptic plasticity, and astrocyte function.[2]
Dysregulated TGF-β signaling through TGFBR1 has been implicated in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. The receptor's dual role in both neuroprotection and neuroinflammation makes it a complex therapeutic target.[3]
TGFBR1 encodes the Type I TGF-beta receptor, a serine/threonine protein kinase that mediates the signaling of transforming growth factor-beta (TGF-β) family cytokines.
- ~567 amino acids in length
- Extracellular domain: Ligand binding
- Transmembrane domain: Single pass
- Serine/threonine kinase domain: Intracellular signaling
- Regulates neuronal differentiation
- Controls astrocyte and oligodendrocyte development
- Essential for proper brain formation
- Neuroprotection: TGF-β signaling is broadly neuroprotective
- Synaptic plasticity: Modulates excitatory/inhibitory balance
- Astrocyte function: Regulates astrocyte reactivity
- Neuroinflammation: Generally anti-inflammatory
- TGFBR1 variants associated with increased risk
- Links to TDP-43 pathology
- Neurons: Moderate expression
- Astrocytes: High expression
- Microglia: Variable, increases with activation
- Oligodendrocytes: Present
- TGF-β1: Recombinant protein
- Small molecule activators: Under development
- SB431542: TGFBR1 kinase inhibitor
- SMAD inhibitors: Downstream blockade
- TGF-β has complex, context-dependent effects
- Peripheral vs. CNS targeting considerations
- Wyss-Coray et al., TGF-beta in Alzheimer's disease (2020)
- Kraft et al., Neuroprotective TGF-beta signaling in PD (2019)
- Endo et al., TGF-beta in ALS pathogenesis (2021)